Research graph
References from Structural engineering of dual-targeting antisense oligonucleotides enhances exon 44 skipping for treating Duchenne muscular dystrophy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(19)32910-1
10.1016/s0140-6736(19)32910-1 · External reference
10.1186/s13018-022-02996-8
10.1186/s13018-022-02996-8 · External reference
Incidence of Duchenne muscular dystrophy in the modern era; an Australian study
10.1038/s41431-022-01138-2 · 2022 · External reference
10.1016/j.nmd.2007.03.002
10.1016/j.nmd.2007.03.002 · External reference
10.1016/s0960-8966(02)00140-2
10.1016/s0960-8966(02)00140-2 · External reference
Unresolved reference
External reference
Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort
2005 · External reference
10.3390/genes15111489
10.3390/genes15111489 · External reference
10.31662/jmaj.2021-0019
10.31662/jmaj.2021-0019 · External reference
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
10.1007/s10974-024-09688-2 · 2025 · External reference
10.3390/biomedicines12040912
10.3390/biomedicines12040912 · External reference
10.1007/s40265-021-01512-2
10.1007/s40265-021-01512-2 · External reference
10.1007/s40265-016-0657-1
10.1007/s40265-016-0657-1 · External reference
10.1007/s40265-020-01267-2
10.1007/s40265-020-01267-2 · External reference
10.1089/hum.2023.026
10.1089/hum.2023.026 · External reference
10.1007/s40265-020-01339-3
10.1007/s40265-020-01339-3 · External reference
Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
10.57264/cer-2023-0086 · 2023 · External reference
10.1002/mus.28075
10.1002/mus.28075 · External reference
Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy
10.1177/22143602251366721 · 2026 · External reference
10.1038/sj.mt.6300095
10.1038/sj.mt.6300095 · External reference
10.1093/nar/gkaf241
10.1093/nar/gkaf241 · External reference
Delpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44
2025 · External reference
Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide
10.1016/j.omtn.2023.102034 · 2023 · External reference
Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy
10.1016/j.xcrm.2024.101901 · 2025 · External reference
10.20944/preprints202505.1948.v1
10.20944/preprints202505.1948.v1 · External reference
10.1093/nar/gks710
10.1093/nar/gks710 · External reference
10.1016/j.molcel.2005.01.017
10.1016/j.molcel.2005.01.017 · External reference
10.1101/2021.08.23.457434
10.1101/2021.08.23.457434 · External reference
Structure and stability of X.G.C mismatches in the third strand of intramolecular triplexes
1991 · External reference
10.1261/rna.055707.115
10.1261/rna.055707.115 · External reference
AFFINImeter: A software to analyze molecular recognition processes from experimental data
10.1016/j.ab.2019.02.031 · 2019 · External reference
10.1016/s0167-4781(99)00138-4
10.1016/s0167-4781(99)00138-4 · External reference
10.1093/nar/23.11.2019
10.1093/nar/23.11.2019 · External reference
10.1074/jbc.271.24.14533
10.1074/jbc.271.24.14533 · External reference
10.1016/s0968-0896(00)00325-4
10.1016/s0968-0896(00)00325-4 · External reference
10.1074/jbc.m500021200
10.1074/jbc.m500021200 · External reference
LNA (locked nucleic acid) and analogs as triplex-forming oligonucleotides
10.1039/b706101c · 2007 · External reference
10.1038/s41598-017-09147-8
10.1038/s41598-017-09147-8 · External reference
10.1093/nar/gkt352
10.1093/nar/gkt352 · External reference
10.1093/nar/gkl1071
10.1093/nar/gkl1071 · External reference
10.1016/j.omtn.2024.102224
10.1016/j.omtn.2024.102224 · External reference
10.1080/14712598.2023.2169070
10.1080/14712598.2023.2169070 · External reference
10.20944/preprints202301.0139.v1
10.20944/preprints202301.0139.v1 · External reference
Renadirsen, a Novel 2’OMeRNA/ENA((R)) Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo
10.3390/cimb43030090 · 2021 · External reference
10.3390/genes8020067
10.3390/genes8020067 · External reference
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
10.1089/nat.2022.0063 · 2023 · External reference
10.1002/humu.20918
10.1002/humu.20918 · External reference
10.1002/humu.23561
10.1002/humu.23561 · External reference
10.1093/nar/gkr810
10.1093/nar/gkr810 · External reference
10.1101/2024.04.18.590021
10.1101/2024.04.18.590021 · External reference
10.3390/molecules181114268
10.3390/molecules181114268 · External reference
10.1093/nar/15.21.8783
10.1093/nar/15.21.8783 · External reference
Ultrafast Cleavage and Deprotection of Oligonucleotides Synthesis and Use of CAc Derivatives
10.1080/07328319708006236 · 1997 · External reference
Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels
10.3389/fcell.2022.830415 · 2022 · External reference
10.1002/mus.27041
10.1002/mus.27041 · External reference
Validation and Detection of Exon Skipping Boosters in DMD Patient Cell Models and mdx Mouse
10.1007/978-1-4939-8651-4_19 · 2018 · External reference
Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models
10.1016/j.omtn.2019.09.020 · 2019 · External reference
10.1002/pro.3943
10.1002/pro.3943 · External reference
10.1038/nprot.2008.104
10.1038/nprot.2008.104 · External reference
10.1021/acs.jctc.4c01164
10.1021/acs.jctc.4c01164 · External reference
10.1021/acs.jcim.3c01153
10.1021/acs.jcim.3c01153 · External reference
10.1016/j.softx.2015.06.001 · 2015 · Admitted local publication
